CRNX Sep 2024 50.000 call
| Previous close | 3.4000 |
| Open | 3.5000 |
| Bid | 3.2000 |
| Ask | 6.5000 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 3.4000 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 263 |
GlobeNewswireEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform livesSAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. Dr. Struthers was selected by an indep
GuruFocus.comInsider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
Chief Scientific Officer Stephen Betz of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 3,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
- GlobeNewswire
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements ma
